Rensselaer Polytechnic Institute granted Alkermes exclusive rights to certain patents and patent applications relating to its compounds designed to modulate opioid receptors.
These compounds represent an opportunity for Alkermes to develop therapeutics for a broad range of diseases and medical conditions, including addiction, pain, and other central nervous system disorders. Alkermes will screen this library of compounds and plans to pursue preclinical work of an undisclosed lead oral compound that has already been identified.
Alkermes will be responsible for the continued R&D of any resulting product candidates. Rensselaer will receive from Alkermes an upfront payment, certain milestone payments relating to clinical development activities, and royalties on products resulting from the agreement.